Syenex provides synthetic biology tools focused on high-efficiency, cell type specific delivery systems for drug developers. Their optimized enveloped vector surface compositions support various programmable cell engineering payloads for therapeutic applications. The company offers access to continuously improving delivery technologies designed for streamlined development from pre-clinical to clinical validation.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current genetic medicine development faces challenges in achieving efficient and cell type-specific delivery of therapeutic payloads, hindering the progress of curative cell and gene therapies. Existing delivery methods often lack the precision needed for targeted delivery and compatibility with diverse cell engineering payloads.
Solution
Syenex offers optimized enveloped vector delivery systems designed to enhance the efficiency and specificity of gene and cell therapy delivery. Their bioengineering technologies enable high-efficiency, cell type-specific targeting in both ex vivo and in vivo applications. The delivery systems are compatible with a variety of programmable cell engineering payload types, supporting a streamlined development path from preclinical prototyping through clinical validation. By providing access to a continuously improving catalog of cell engineering and delivery technologies, Syenex aims to free up resources for drug developers to focus on their therapeutic insights.
Target Audience
Syenex's primary customers are drug developers and biotechnologists focused on advancing genetic medicines and curative cell and gene therapies.
Features
- Optimized enveloped vector surface compositions for high-efficiency, cell type-specific delivery
- Delivery systems compatible with a range of programmable cell engineering payload types, including retroviral integrase
- Technologies designed for scale, with CDMO integrations and regulatory support
- Access to a continuously improving catalog of cell engineering and delivery technologies